P193: Prevalence, penetrance, and phenotypic expression of cardiomyopathy-associated genetic variants in a quaternary medical center-based biobank

Introduction: Cardiomyopathies (CM) are a leading cause of heart failure.Identification of genetic risk preemptively may allow detection of the earliest phenotypic manifestations through implementation of interval-based cardiac screening.Previous population-based genetic screening studies have inadequate phenotyping and limited follow-up.Methods: We analyzed 52,863 patients from a quaternary medical center-based biobank cohort for reportable variants in 22-cardiomyopathy genes.Prioritization of genetic variants was performed using Semi-Automated Variant Interpretation, a novel software that has been previously developed and validated at our center.Prioritized variants were then manually curated by at least 2 independent variant interpretation specialists.Clinical phenotypes and outcomes of participants with likely pathogenic/pathogenic (LP/P) variants were determined.Results: LP/P cardiomyopathy variants were present in ~1% of our cohort (n=427) within the following genes: BAG3 (n=3), DES (n=1), DSG2 (n=4), DSP (n=36), FLNC (n=20), LMNA (n=9), MYBPC3 (n=123), MYH7 (n=67), MYL2 (n=2), MYL3 (n=1), PKP2 (n=45), RBM20 (n=1), TNNC1 (n=1), TNNI3 (n=18), TNNT2 (n=5), TPM1 (n=3), TTN (n=101).A definitive disease penetrance defined as heart failure or cardiomyopathy was found in 34% (n=145) of genotype positive (G+) individuals.Possible disease penetrance defined as presence of structural heart disease identified by echocardiography was found in an additional 16% (n=68) of participants (eg, concentric left ventricular hypertrophy, diastolic dysfunction, biatrial or left/right atrial enlargement).Combined definitive and possible disease penetrance was found in 50% (n=213) of G+ individuals.Arrhythmias and/or cardiac conduction disease (eg, atrial fibrillation, atrioventricular block, ventricular arrhythmia) were present in 41% (n=176) of G+ individuals.Conclusion: Cardiomyopathy associated LP/P variants are present in a small subset of a large quaternary medical center population as previously reported but unlike prior studies, disease penetrance manifesting as cardiac structural abnormalities and heart failure is high in G+ individuals.

Authors

Institutions

Publication Details

Journal
Genetics in Medicine Open
Published
2025-01-01
DOI
https://doi.org/10.1016/j.gimo.2025.102158
Primary Topic
Cardiomyopathy and Myosin Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P193: Prevalence, penetrance, and phenotypic expression of cardiomyopathy-associated genetic variants in a quaternary medical center-based biobank

Joseph Farris, Josh Bublitz, Naveen L. Pereira, Luca Fazzini et al.
Genetics in Medicine Open
Cardiomyopathy and Myosin Studies
article

P193: Prevalence, penetrance, and phenotypic expression of cardiomyopathy-associated genetic variants in a quaternary medical center-based biobank

Joseph Farris, Josh Bublitz, Naveen L. Pereira, Luca Fazzini, Patricia A. Pellikka, Marta Figueiral, Jennifer Arroyo, Eric W. Klee, Jia Tan, Rory J. Olson, Alessia Paldino, Janet E. Olson
article en

Abstract

Introduction: Cardiomyopathies (CM) are a leading cause of heart failure.Identification of genetic risk preemptively may allow detection of the earliest phenotypic manifestations through implementation of interval-based cardiac screening.Previous population-based genetic screening studies have inadequate phenotyping and limited follow-up.Methods: We analyzed 52,863 patients from a quaternary medical center-based biobank cohort for reportable variants in 22-cardiomyopathy genes.Prioritization of genetic variants was performed using Semi-Automated Variant Interpretation, a novel software that has been previously developed and validated at our center.Prioritized variants were then manually curated by at least 2 independent variant interpretation specialists.Clinical phenotypes and outcomes of participants with likely pathogenic/pathogenic (LP/P) variants were determined.Results: LP/P cardiomyopathy variants were present in ~1% of our cohort (n=427) within the following genes: BAG3 (n=3), DES (n=1), DSG2 (n=4), DSP (n=36), FLNC (n=20), LMNA (n=9), MYBPC3 (n=123), MYH7 (n=67), MYL2 (n=2), MYL3 (n=1), PKP2 (n=45), RBM20 (n=1), TNNC1 (n=1), TNNI3 (n=18), TNNT2 (n=5), TPM1 (n=3), TTN (n=101).A definitive disease penetrance defined as heart failure or cardiomyopathy was found in 34% (n=145) of genotype positive (G+) individuals.Possible disease penetrance defined as presence of structural heart disease identified by echocardiography was found in an additional 16% (n=68) of participants (eg, concentric left ventricular hypertrophy, diastolic dysfunction, biatrial or left/right atrial enlargement).Combined definitive and possible disease penetrance was found in 50% (n=213) of G+ individuals.Arrhythmias and/or cardiac conduction disease (eg, atrial fibrillation, atrioventricular block, ventricular arrhythmia) were present in 41% (n=176) of G+ individuals.Conclusion: Cardiomyopathy associated LP/P variants are present in a small subset of a large quaternary medical center population as previously reported but unlike prior studies, disease penetrance manifesting as cardiac structural abnormalities and heart failure is high in G+ individuals.

Genetics in Medicine OpenVol. 3
WinnMed (US)
Gender equality
Openalex Percentile: Top 92%
Cardiomyopathy and Myosin Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.